Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100...
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with...
Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study...
PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolledAdditional analysis of data from a Phase 1b...
FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib’s...
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from...
3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 continues to demonstrate...
Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in...
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations,...
TORONTO, ON / ACCESS Newswire / October 17, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that...
Building a bridge between wellness and clinical care, Samsung and Xealth will create a health ecosystem that helps clinicians and...
MCLEAN, Va., Oct. 17, 2025 /PRNewswire/ -- ID.me and Flexpa today announced a partnership to make it easier and safer for...
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage...
BiomX believes that it has fully addressed the FDA’s queries related to the third-party nebulizer used to deliver BX004, which...
PLEASANTON, Calif. and MIAMI, Oct. 16, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and OpenEvidence today announced the formation of...
The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes,...
BOSTON, Oct. 16, 2025 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials, has announced a...
First HopeHealth Clinical Trial Marks Major Milestone for Access to Medical Research in Rural South CarolinaOriginally published on HopeHealth NORTHAMPTON,...
First-time presentation examining bone outcomes in early postmenopausal womenJERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX),...